These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 7906417)

  • 1. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
    Carlson KM; Dou S; Chi D; Scavarda N; Toshima K; Jackson CE; Wells SA; Goodfellow PJ; Donis-Keller H
    Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1579-83. PubMed ID: 7906417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
    Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
    J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
    Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G
    Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germ line mutation in the RET proto-oncogene associated with familial multiple endocrine neoplasia type 2B: a case report.
    Ishida O; Zeki K; Morimoto I; Yamamoto S; Fujihira T; Eto S
    Jpn J Clin Oncol; 1995 Jun; 25(3):104-8. PubMed ID: 7596047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
    Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
    Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
    Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
    Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RET proto-oncogene and cancer.
    Donis-Keller H
    J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A.
    Quadro L; Panariello L; Salvatore D; Carlomagno F; Del Prete M; Nunziata V; Colantuoni V; Di Giovanni G; Brandi ML; Mannelli M
    J Clin Endocrinol Metab; 1994 Aug; 79(2):590-4. PubMed ID: 7913936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
    Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
    Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
    Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
    Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
    Mulligan LM; Kwok JB; Healey CS; Elsdon MJ; Eng C; Gardner E; Love DR; Mole SE; Moore JK; Papi L
    Nature; 1993 Jun; 363(6428):458-60. PubMed ID: 8099202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature.
    Kahn MA; Cote GJ; Gagel RF
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1996 Sep; 82(3):288-94. PubMed ID: 8884827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.